- AuthorisedTherapeutic use (Phase IV)
Optimization of Dupilumab Maintenance Dosing in Eosinophilic Esophagitis: A Phase IV, Randomized, Controlled, Single-Blind, Non-Inferiority Study
This clinical trial looks at whether adults with eosinophilic oesophagitis (an allergic inflammation of the food pipe) can stay healthy on a lower or less frequent maintenance dose of dupilumab. The study aims to find out if reducing the dose keeps symptoms away safely over one year.
For: Eosinophilic EsophagitisNetherlands - RecruitingPHASE4
A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.
This study looks at a new treatment called dupilumab for people aged 40-85 with a severe lung condition called COPD. It aims to see if the treatment reduces lung inflammation and improves breathing and quality of life.
For: Chronic Obstructive Pulmonary DiseaseUnited States · Argentina · Austria - Active not recruitingPHASE3
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
This study looks at two medicines, upadacitinib and dupilumab, for children aged 2 to 11 with moderate to severe eczema (atopic dermatitis). It wants to see which one works better and has fewer side effects for children who need strong treatment.
For: Atopic DermatitisUnited States · Argentina · Australia - Recruiting
Study to Evaluate Long-term Effectiveness and Safety, Patient Characteristics and Subjective Patient-reported Outcomes of Dupilumab in Patients With Chronic Obstructive Pulmonary Disease (COPD) Under Real-world Conditions
This study looks at how a new medicine, dupilumab, works for people with a lung condition called COPD in their everyday lives. Researchers will observe over two years how it affects their health, quality of life, and safety.
For: Chronic Obstructive Pulmonary Disease (COPD)Germany - Recruiting
Molecular Signatures in Inflammatory Skin Disease
This study looks at people with skin conditions like eczema and psoriasis to understand how their bodies respond to new treatments. We want to find patterns in their genes and cells to help doctors choose the best medicine for each person in the future.
For: Atopic Dermatitis · PsoriasisGermany - Active not recruitingPHASE3
A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 2)
This study looks at whether a new medicine, Dupilumab, can help reduce the itching caused by a skin condition called Lichen Simplex Chronicus (LSC). It compares Dupilumab injections to a dummy treatment (placebo) in adults with moderate to severe LSC.
For: Lichen Simplex ChronicusUnited States · Argentina · Belgium - Active not recruitingPHASE3
Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD)
This study looks at the long-term safety of a treatment called dupilumab for children and teenagers with eczema (atopic dermatitis). It also checks how well it works and how the body handles the medicine over time. There's an optional part looking at a new way to give the medicine.
For: Atopic DermatitisUnited States · Canada · Czechia - Active not recruiting
Real-World Effectiveness of Dupilumab in Patients With Prurigo Nodularis: An Observational Study
This study looks at how a medicine called dupilumab works for people with prurigo nodularis in everyday life. Researchers want to see how well it helps manage the condition and how it's being used by patients in different countries.
For: Prurigo NodularisUnited States · Canada · China - Active not recruitingPHASE3
A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 1)
This study is testing a new injection, Dupilumab, for people over 18 with persistent itchy skin patches called Lichen Simplex Chronicus. It aims to see if the injection reduces itching better than a dummy injection.
For: Lichen Simplex ChronicusUnited States · Argentina · Canada - Active not recruiting
Study of Patients Receiving DUPIXENT® for Atopic Dermatitis (AD)
This study looks at how a medicine called Dupixent works for people with eczema (atopic dermatitis) in their everyday lives. We want to see how it's used, how well it helps, and if there are any side effects over time for people aged 12 and over.
For: Dermatitis, AtopicUnited States · Canada - Active not recruitingPHASE1
An Active Comparator Safety Study Evaluating the Combination of APG777 + APG990 in Moderate-to-Severe Atopic Dermatitis
This study is looking at how safe and effective two new medicines (APG777 + APG990) are when used together for moderate to severe eczema, compared to an existing treatment (dupilumab).
For: Atopic DermatitisAustralia · Canada · New Zealand - Active not recruitingPHASE4
A Study Assessing Esophageal Function and Remodeling With Dupilumab Compared With Placebo for 24 Weeks Followed by 104 Weeks Open Label in Adult Participants With EoE (REMOdeling With Dupilumab in Eosinophilic Esophagitis Long-term Trial)
This study looks at how a medicine called dupilumab helps adults with Eosinophilic Oesophagitis (EoE). We want to see if it improves how the gullet works and if any damage heals, compared to a dummy medicine, over 2.5 years.
For: Eosinophilic OesophagitisUnited States · Brazil · Canada - Active not recruitingPHASE4
A Study of Long-term Effect of Dupilumab on Skin Barrier Function in Pediatric Participants With Atopic Dermatitis
This study looks at how a medicine called dupilumab (Dupixent®) affects the skin barrier in children aged 6-14 with moderate to severe eczema over two years. It aims to understand if the medicine helps the skin stay healthy.
For: Dermatitis AtopicUnited States · United Kingdom - Active not recruitingPHASE2
A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD)
This study is testing a new medicine called JNJ-95475939 for people with moderate to severe eczema (atopic dermatitis). Researchers want to see if it works better than a dummy medicine (placebo) to improve skin and reduce itching.
For: Dermatitis, AtopicUnited States · Argentina · Brazil - Enrolling by invitationPHASE3
Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)
This study is testing a new medicine, dupilumab, for children aged 2-5 who have asthma or wheezing that’s hard to control. It aims to see how well it works and if it's safe over time.
For: Wheezing · AsthmaUnited States · Argentina · Brazil - Active not recruitingPHASE4
Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma
This study is looking at whether a medicine called dupilumab can help adults with moderate to severe asthma keep their lungs working better over time. It compares dupilumab to standard asthma care to see if it can prevent lung function from getting worse. It's a long-term study.
For: AsthmaUnited States · Belgium · Brazil - Recruiting
Mind and Skin - the Neurocutaneous Axis in Atopic Eczema
This study, called 'Mind and Skin,' looks at how severe eczema affects the brain, mental health, and thinking abilities in young people aged 12-18. It examines links between inflammation, itching, disturbed sleep, and how new eczema treatments might help.
For: Atopic DermatitisUnited Kingdom